select a format

Single User License
USD 2000 INR 129700
Site License
USD 4000 INR 259400
Corporate User License
USD 6000 INR 389100

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Streptococcal Infections-Pipeline Review, H1 2016

Streptococcal Infections-Pipeline Review, H1 2016


  • Products Id :- GMDHC8177IDB
  • |
  • Pages: 78
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Streptococcal Infections-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Streptococcal Infections-Pipeline Review, H1 2016', provides an overview of the Streptococcal Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Streptococcal Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcal Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Streptococcal Infections

The report reviews pipeline therapeutics for Streptococcal Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Streptococcal Infections therapeutics and enlists all their major and minor projects

The report assesses Streptococcal Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Streptococcal Infections

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Streptococcal Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Streptococcal Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Streptococcal Infections Overview 9

Therapeutics Development 10

Pipeline Products for Streptococcal Infections-Overview 10

Pipeline Products for Streptococcal Infections-Comparative Analysis 11

Streptococcal Infections-Therapeutics under Development by Companies 12

Streptococcal Infections-Therapeutics under Investigation by Universities/Institutes 13

Streptococcal Infections-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Streptococcal Infections-Products under Development by Companies 16

Streptococcal Infections-Products under Investigation by Universities/Institutes 17

Streptococcal Infections-Companies Involved in Therapeutics Development 18

Absynth Biologics Limited 18

AstraZeneca Plc 19

Centauri Therapeutics Limited 20

ContraFect Corporation 21

Emergent BioSolutions Inc. 22

GlaxoSmithKline Plc 23

Helix BioMedix, Inc. 24

Merck & Co., Inc. 25

MGB Biopharma Limited 26

Sealife PHARMA GMBH 27

Sequoia Sciences, Inc. 28

Sumitomo Dainippon Pharma Co., Ltd. 29

Trellis Bioscience, Inc. 30

Wellstat Vaccines, LLC 31

Streptococcal Infections-Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

ATx-201-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

AZ-6142-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

CF-305-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

EV-035-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

firmocidin-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

HB-1345-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

J8-CRM197-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

MGBBP-3-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Monoclonal Antibodies for Group A Streptococcus Infections-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Monoclonal Antibody to Inhibit Coagulase for Streptococcus Infections-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Polysaccharides for Streptococcal Infections-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

SLP-0901-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

SLP-0905-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

SM-295291-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

SM-369926-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules for Bacterial Infections-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Small Molecules to Inhibit DHFR for Infectious Diseases-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Streptococcus (trivalent) vaccine-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

streptococcus [serotype B] (multivalent) vaccine-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Streptococcus pyogenes (30-valent) vaccine-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Streptococcus pyogenes vaccine-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Streptococcus pyogenes vaccine-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Streptococcus pyogenes vaccine-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Streptococcus vaccine-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Streptococcal Infections-Dormant Projects 72

Streptococcal Infections-Discontinued Products 74

Streptococcal Infections-Product Development Milestones 75

Featured News & Press Releases 75

Aug 25, 2015: Streptococcus Vaccine Developed by UTHSC Professor of Medicine James B. Dale to Begin Clinical Trial 75

Jun 01, 2015: Researchers create new combination vaccine to fight Streptococcus A 75

Appendix 77

Methodology 77

Coverage 77

Secondary Research 77

Primary Research 77

Expert Panel Validation 77

Contact Us 77

Disclaimer 78

List of Figures

Number of Products under Development for Streptococcal Infections, H1 2016 10

Number of Products under Development for Streptococcal Infections-Comparative Analysis, H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Number of Products under Investigation by Universities/Institutes, H1 2016 13

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Assessment by Monotherapy Products, H1 2016 32

Number of Products by Top 10 Targets, H1 2016 33

Number of Products by Stage and Top 10 Targets, H1 2016 33

Number of Products by Mechanism of Actions, H1 2016 35

Number of Products by Stage and Mechanism of Actions, H1 2016 35

Number of Products by Routes of Administration, H1 2016 37

Number of Products by Stage and Routes of Administration, H1 2016 37

Number of Products by Molecule Types, H1 2016 39

Number of Products by Stage and Molecule Types, H1 2016 39

List of Tables

Number of Products under Development for Streptococcal Infections, H1 2016 10

Number of Products under Development for Streptococcal Infections-Comparative Analysis, H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Number of Products under Investigation by Universities/Institutes, H1 2016 13

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Development, H1 2016 15

Products under Development by Companies, H1 2016 16

Products under Investigation by Universities/Institutes, H1 2016 17

Streptococcal Infections-Pipeline by Absynth Biologics Limited, H1 2016 18

Streptococcal Infections-Pipeline by AstraZeneca Plc, H1 2016 19

Streptococcal Infections-Pipeline by Centauri Therapeutics Limited, H1 2016 20

Streptococcal Infections-Pipeline by ContraFect Corporation, H1 2016 21

Streptococcal Infections-Pipeline by Emergent BioSolutions Inc., H1 2016 22

Streptococcal Infections-Pipeline by GlaxoSmithKline Plc, H1 2016 23

Streptococcal Infections-Pipeline by Helix BioMedix, Inc., H1 2016 24

Streptococcal Infections-Pipeline by Merck & Co., Inc., H1 2016 25

Streptococcal Infections-Pipeline by MGB Biopharma Limited, H1 2016 26

Streptococcal Infections-Pipeline by Sealife PHARMA GMBH, H1 2016 27

Streptococcal Infections-Pipeline by Sequoia Sciences, Inc., H1 2016 28

Streptococcal Infections-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 29

Streptococcal Infections-Pipeline by Trellis Bioscience, Inc., H1 2016 30

Streptococcal Infections-Pipeline by Wellstat Vaccines, LLC, H1 2016 31

Assessment by Monotherapy Products, H1 2016 32

Number of Products by Stage and Target, H1 2016 34

Number of Products by Stage and Mechanism of Action, H1 2016 36

Number of Products by Stage and Route of Administration, H1 2016 38

Number of Products by Stage and Molecule Type, H1 2016 40

Streptococcal Infections-Dormant Projects, H1 2016 72

Streptococcal Infections-Dormant Projects (Contd..1), H1 2016 73

Streptococcal Infections-Discontinued Products, H1 2016 74

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Absynth Biologics Limited

AstraZeneca Plc

Centauri Therapeutics Limited

ContraFect Corporation

Emergent BioSolutions Inc.

GlaxoSmithKline Plc

Helix BioMedix, Inc.

Merck & Co., Inc.

MGB Biopharma Limited

Sealife PHARMA GMBH

Sequoia Sciences, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Trellis Bioscience, Inc.

Wellstat Vaccines, LLC

Streptococcal Infections Therapeutic Products under Development, Key Players in Streptococcal Infections Therapeutics, Streptococcal Infections Pipeline Overview, Streptococcal Infections Pipeline, Streptococcal Infections Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com